直 Japanese PDF Font
  • Our Professionals
  • Our Work
  • Our Insights
  • Offices
  • Firm
  • Careers
Finnegan
  • Articles & Books
    • Ad Law Buzz Blog
    • At the PTAB Blog
    • European IP Blog
    • Federal Circuit IP Blog
    • INCONTESTABLE® Blog
    • Prosecution First Blog
  • Events & Webinars
  • IP Updates
  • Podcasts
    • AI + Finnegan
    • AI + Copyright
    • AI + Patent
    • AI + Privacy
    • AI + Trade Secrets
    • AI + Trademark
  • Unified Patent Court (UPC) Hub

Federal Circuit IP Blog

Biotechnology Patent Survives a § 101 Challenge at the Federal Circuit

July 15, 2016

Authored and Edited by Elizabeth D. Ferrill; Meredith H. Boerschlein*, Jeff T. Watson

In Rapid Litigation Management Ltd. v. CellzDirect, Inc., No. 15-1570 (Fed. Cir. July 5, 2016), the Federal Circuit vacated and remanded the district court’s summary judgment determination that the patent-in-suit is directed to patent-ineligible subject matter and therefore invalid.

Rapid Litigation Management sued CellzDirect for infringing its patent covering a method of preserving hepatocytes (liver cells). CellzDirect moved for summary judgment alleging the patent was invalid under 35 U.S.C. § 101. The district court agreed, applying the two-part test for patent eligibility established in Mayo Collaborative Servs. v. Prometheus Labs., Inc. and confirmed in Alice Corp. v. CLS Bank International. According to the district court, the claims concerned a law of nature (hepatocytes’ ability to survive multiple freeze-thaw cycles), and the well-known freezing method did not provide the requisite “inventive concept.”

On appeal, the Federal Circuit disagreed with the district court’s application of the Mayo/Alice test. Unlike the court below, the Federal Circuit found that the patent did not concern a law of nature, but rather “a new and useful laboratory technique[.]” As the Court further articulated, even if the patent is directed to a law of nature, it is eligible under step two. The twice-frozen process provides an inventive concept.

In reaching its conclusion, the Court added two points: (1) “patent-eligibility does not turn on ease of execution or obviousness of application”; and (2) “while pre-emption is not the test for determining patent-eligibility,” the district court’s findings that the patent “does not lock up the natural law in its entirety” and that “LTC has already managed to engineer around the patent” are in accord with the Court’s conclusion that “the patent is not ‘directed to’ a patent-ineligible building block of human ingenuity.” Thus, the Court vacated and remanded the district court’s summary judgment grant.

 

*Meredith H. Boerschlein is a Law Clerk at Finnegan.

Tags

35 U.S.C. § 101, summary judgment

Contacts

Elizabeth D. Ferrill
Partner
Washington, DC
+1 202 408 4445
Email

Copyright © 2016 Finnegan, Henderson, Farabow, Garrett & Dunner, LLP. 


DISCLAIMER: Although we wish to hear from you, information exchanged in this blog cannot and does not create an attorney-client relationship. Please do not post any information that you consider to be personal or confidential. If you wish for Finnegan, Henderson, Farabow, Garrett & Dunner, LLP to consider representing you, in order to establish an attorney-client relationship you must first enter a written representation agreement with Finnegan. Contact us for additional information. One of our lawyers will be happy to discuss the possibility of representation with you. Additional disclaimer information.

Related Insights

Conference

7th International Conference on Biofuels and Bioenergy

June 25-26, 2026

Edinburgh

Conference

BIA Start-up Festival

May 21, 2026

London

Conference

19th Annual Forum on Pharma & Biotech Patent Litigation in Europe

May 19-20, 2026

Amsterdam

Conference

2026 Advanced Chemical & Biotech Patent Institute

May 11-12, 2026

San Francisco

Workshop

Protecting Innovation in the Life Sciences: Updates and Key Trends in Pharmaceutical and Biotechnology IP Law

May 7, 2026

Cambridge

Articles

D. Mass. Patent Litigation Update, March 2026

D. Mass. Patent Litigation Update: March 2026

May 4, 2026

European IP Blog

T 0137/24 and Securing Effective Protection for Biologics

May 1, 2026

Conference

THRiVE 2026

April 30, 2026

Richmond

Articles

D. Mass. Patent Litigation Update, March 2026

D. Mass. Patent Litigation Update: February 2026

March 26, 2026

Due to international data regulations, we’ve updated our privacy policy. Click here to read our privacy policy in full.

  • Privacy
  • Disclaimer
  • Legal Notices
  • Fraud Alert
  • EEO Statement
  • Cookies
  • Contact Us

© 2026 Finnegan, Henderson, Farabow, Garrett & Dunner, LLP